A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma

NCT02998047 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Poor recruitment

Conditions

Refractory Multiple Myeloma

Interventions

DRUG: Lintuzumab AC 225

Sponsor

Actinium Pharmaceuticals